Mr. Trudeau joined VBL Therapeutics in January 2022 and brings over 25 years of US and International experience commercializing complex biological solutions for patients in need. He served most recently as head of the US business team at bluebird bio where he led design and implementation of their commercial operating model and was accountable for all aspects of US commercialization for an innovative gene therapy portfolio. Prior to that, Matt served at Biogen where he led Asia-Pacific business operations for a portfolio of biologics targeting neurologic and hematologic diseases. At Biogen, he also led global strategic design and implementation of the company's first companion diagnostic platform. Matt started his career at Genzyme where he advanced through sales and marketing roles of increasing impact in the diagnostics and surgical oncology segments. Matt holds a MS degree from Northeastern University and a BA degree from Colby College.

Source: Vascular Biogenics Ltd. on 08/26/2022